Navigation Links
Brain scans show effects of Parkinson's drug
Date:11/30/2010

AUDIO: Neuroscientists at Washington University School of Medicine in St. Louis have used a new brain imaging technique to determine that an investigational parkinsons disease drug is affecting blood flow in...

Click here for more information.

Neuroscientists using a new brain imaging technique could see an investigational drug for Parkinson's disease get into a patient's brain and affect blood flow in several key structures, an indicator the drug may be effective.

The study represents the first use of the technique in humans called perfusion MRI to test a drug still in development, the lead investigator says. In the future, similar brain scans could speed the development of new drugs and help clinicians learn whether established drugs are working, according to the researchers at Washington University School of Medicine in St. Louis.

The research team reports those findings Dec. 1 in The Journal of Neuroscience.

Perfusion MRI allowed the researchers to measure blood flow in the brain and even to determine the precise blood level of the drug, SYN115, needed to affect particular regions of the brain. They were able to demonstrate that the drug may be a viable therapy when combined with levodopa (L-Dopa), currently the most effective treatment for patients with Parkinson's disease.

The study, a Phase 2 clinical trial, used two doses of the investigational drug. Its safety already had been tested in healthy volunteers. The goal was to determine what might be a reasonable dose for a larger clinical trial in Parkinson's disease.

Unlike L-Dopa, which works through the brain's dopamine system, SYN115 interacts with the brain's adenosine A2a receptor. That receptor can modify the effects of the neurotransmitters glutamate and dopamine and is thought to be a potential therapeutic target not only for Parkinson's disease but also for insomnia, pain, drug addiction and depression.

"This study is important because it demonstrates this may be a useful approach for studying investigational drugs," says lead investigator Kevin J. Black, MD. "We were able to determine both that the drug gets into the brain to exert its effects and that it has a larger effect at a higher dose."

Black, a professor of psychiatry, of neurology, of neurobiology and of radiology, and his team used a new, FDA-approved type of perfusion MRI called arterial spin labeling (ASL), which uses MRI scans to measure blood flow in the brain. A similar technique uses positron emission tomography (PET) scans. Older forms of MRI scanning could not provide scientists with similar functional measurements.

Although PET scans can measure many of the same things, a large number of medical centers don't have PET scanners, and depending how it's done, PET may cost more, Black explains. The previous method of measuring blood flow with functional MRI is called BOLD scanning (Blood Oxygen Level Dependent).

"That's a wonderful technique for watching someone's brain respond to a question or a task or to compare blood flow changes over short periods of time," he says. "But it's not very helpful in determining the effects of drugs that might not influence the brain for 30 minutes or an hour. The ASL method works much better at comparing brain activity over that longer time period."

SYN115 probably is not a candidate to replace L-Dopa, Black says, but if used with L-Dopa, he believes it may boost that drug's therapeutic benefit and reduce its side effects. His team tested 21 Parkinson's patients, comparing ASL functional MRI scans among patients who took only L-Dopa and those who took L-Dopa combined with either 20 milligrams or 60 milligrams of SYN115. Patients who received SYN115 experienced decreased blood flow in specific brain structures, with the biggest decreases occurring in the thalamus.

"The nerve cells that send signals to the thalamus are mostly inhibitory in nature," Black says. "So we believe these decreases represent the brain taking its foot off of the brake pedal. The more drug in the system, the less 'braking' influence there is on the thalamus, which would then allow the thalamus to send positive signals to the brain's cortex, where movements are initiated."

Decreases in blood flow were more significant in subjects who had higher blood levels of the investigational drug. More study will be required to learn whether even higher doses might have a bigger influence on brain activity, Black says. It also will be important, he adds, to determine whether the decreased blood flow seen in the MRI scans will ease clinical symptoms of Parkinson's disease, such as tremors, weakness, stiffness and difficulty walking.

But it is clear the drug is influencing brain function, he says. Even if this drug does not have a big impact, the method his team used to study the drug could influence future pharmaceutical research.

"This could shorten the time it takes to get medications to market because you don't need as many patients or as much time to determine whether a drug has an effect in the brain," he says. "This imaging technique could make it possible to significantly shorten the time from drug discovery to the launch of large, clinical studies to learn whether it truly is effective."

And the technique has implications beyond Parkinson's disease.

"One example might be depression," Black says. "Antidepressant drugs work for some people and not for others. The drugs exert many effects within the first two hours, but often they don't begin to relieve depression symptoms for a month or more. Theoretically, this imaging test could determine within hours whether we're going to help patients, rather than waiting weeks to see if the drug is alleviating depression."


'/>"/>

Contact: Jim Dryden
jdryden@wustl.edu
314-286-0110
Washington University School of Medicine
Source:Eurekalert  

Related medicine news :

1. Acupuncture changes brains perception and processing of pain
2. Researchers identify a molecular switch that controls neuronal migration in the developing brain
3. Chronic high cholesterol diet produces brain damage
4. Better Helmet Design Might Lower Soldiers Risk for Brain Injury
5. Mayo Clinic study finds aggressive surgery is best for children with brain tumors
6. Protein found to predict brain injury in children on ECMO life support
7. Young Motorcycle Riders Suffering More Brain Injuries
8. Researchers identify PTSD measures for use in traumatic brain injury research
9. Key Brain Area for Vision May Be Organized by Color
10. Tiny Trojan horses attack brain cancer cells
11. Early Pot Use May Harm Brain More: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Brain scans show effects of Parkinson's drug
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... their offering. ... The global chromatography market to grow at a ... Market 2016-2020, has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
(Date:12/8/2016)... , December 8, 2016 ... "Sugar-Based Excipients Market by Product (Actual Sugars, Sugar ... (Filler & Diluent, Tonicity Agents), Formulation (Oral, Topical, ... MarketsandMarkets, the market has witnessed healthy growth during ... at a CAGR of 4.3% between 2016 and ...
(Date:12/8/2016)... , Dec. 8, 2016  Agenovir Corporation, a ... novel antiviral therapeutics, today announced that it appointed ... officer and a member of the board of ... executive with a deep background in both founding ... founder of Agenovir, co-president of Chan Zuckerberg  Biohub ...
Breaking Medicine Technology: